Abstract
Sirolimus (rapamycin), a macrolide antibiotic approved for use as an immunosuppressive agent in the prevention of organ rejection, is a cell proliferation inhibitor and regulator of the immune response which acts through inhibition of TOR (target of rapamycin), a kinase essential to cell cycle progression. Recent studies suggest that the TOR pathway is critical to overall cell function, and at a basic mechanistic level, may be a regulator and potential therapeutic target involved in many of the major (and minor) disorders seen in man today. Cardiovascular diseases including restenosis following percutaneous coronary intervention as well as the more widespread condition of atherosclerosis, share this common involvement of TOR. The present report addresses the current state of intervention in cardiovascular disorders with Sirolimus and similar inhibitors of TOR, including the rationale for this approach and the successes observed to date. Success of the first drug-eluting stent to locally treat restenosis in the clinic is discussed, as are preclinical studies addressing a role in overall atherosclerosis in animal models. In addition, due to the known toxicities when given systemically, an approach for targeted delivery to local areas of vascular disease is discussed.
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Paclitaxel, Eluting Stent Systems, Coronary artery, neointimal hyperplasia, restenosis, taxol, coronary artery disease, drug-eluting stent, clinical trials, bare metal stent, angioplasty, sirolimus-eluting stents, Chemotherapy, -tubulin, lipophilicity, Palmaz-Schatz stents, intraintimal hemorrhage, Antiplatelet therapy, clopidogrel, angiographic stenosis, myocardial infarction, Academic Research Consortium, thrombosis, Stenting of Saphenous Vein Grafts, vascular brachytherapy, brachytherapy, chronic total occlusions, SYNTAX trial, XIENCE V stent, femoropopliteal disease
Current Pharmaceutical Design
Title: Sirolimus and its Analogs and its Effects on Vascular Diseases
Volume: 16 Issue: 36
Author(s): Steven J. Adelman
Affiliation:
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Paclitaxel, Eluting Stent Systems, Coronary artery, neointimal hyperplasia, restenosis, taxol, coronary artery disease, drug-eluting stent, clinical trials, bare metal stent, angioplasty, sirolimus-eluting stents, Chemotherapy, -tubulin, lipophilicity, Palmaz-Schatz stents, intraintimal hemorrhage, Antiplatelet therapy, clopidogrel, angiographic stenosis, myocardial infarction, Academic Research Consortium, thrombosis, Stenting of Saphenous Vein Grafts, vascular brachytherapy, brachytherapy, chronic total occlusions, SYNTAX trial, XIENCE V stent, femoropopliteal disease
Abstract: Sirolimus (rapamycin), a macrolide antibiotic approved for use as an immunosuppressive agent in the prevention of organ rejection, is a cell proliferation inhibitor and regulator of the immune response which acts through inhibition of TOR (target of rapamycin), a kinase essential to cell cycle progression. Recent studies suggest that the TOR pathway is critical to overall cell function, and at a basic mechanistic level, may be a regulator and potential therapeutic target involved in many of the major (and minor) disorders seen in man today. Cardiovascular diseases including restenosis following percutaneous coronary intervention as well as the more widespread condition of atherosclerosis, share this common involvement of TOR. The present report addresses the current state of intervention in cardiovascular disorders with Sirolimus and similar inhibitors of TOR, including the rationale for this approach and the successes observed to date. Success of the first drug-eluting stent to locally treat restenosis in the clinic is discussed, as are preclinical studies addressing a role in overall atherosclerosis in animal models. In addition, due to the known toxicities when given systemically, an approach for targeted delivery to local areas of vascular disease is discussed.
Export Options
About this article
Cite this article as:
J. Adelman Steven, Sirolimus and its Analogs and its Effects on Vascular Diseases, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454923
DOI https://dx.doi.org/10.2174/138161210794454923 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Are the Pleiotropic Effects of Telmisartan Clinically Relevant?
Current Pharmaceutical Design Five Markers Capable to Identify Passive Smoking Exposure Associated with Endothelial Dysfunction in Healthy Individuals
Current Hypertension Reviews Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Lipid Lowering Drugs and Gallstones: A Therapeutic Option?
Current Pharmaceutical Design Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Vesicovaginal Fistula
Current Women`s Health Reviews Recent Advances in Polymer-based Wound Dressings for the Treatment of Diabetic Foot Ulcer: An Overview of State-of-the-art
Current Drug Targets Left Ventricular 2-[<sup>18</sup>F]-Fluoro-2-Deoxy-D-Glucose Uptake Using Modified Oral Glucose Loading Protocol With Pre-Medicated Niacin On Positron Emission Tomography/Computed Tomography - A Preliminary Study
Current Molecular Imaging (Discontinued) Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design